News stories about Acorda Therapeutics (NASDAQ:ACOR) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.8543446076981 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Acorda Therapeutics (ACOR) Rating Lowered to Sell at ValuEngine (americanbankingnews.com)
- Zacks: Analysts Expect Acorda Therapeutics Inc (ACOR) Will Announce Earnings of $1.09 Per Share (americanbankingnews.com)
- Critical Survey: Intra-Cellular Therapies (ITCI) versus Acorda Therapeutics (ACOR) (americanbankingnews.com)
- Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference (finance.yahoo.com)
- Options Traders Expect Huge Moves in Acorda Therapeutics (ACOR) Stock (finance.yahoo.com)
Acorda Therapeutics (ACOR) traded up $0.20 during trading on Friday, hitting $24.05. The stock had a trading volume of 561,803 shares, compared to its average volume of 776,325. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $1,114.92, a price-to-earnings ratio of -19.88 and a beta of 1.63.
In other news, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the completion of the transaction, the insider now directly owns 33,150 shares of the company’s stock, valued at $680,569.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Lawrence sold 31,000 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $27.58, for a total value of $854,980.00. Following the completion of the transaction, the insider now directly owns 5,275 shares of the company’s stock, valued at $145,484.50. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Acorda Therapeutics (ACOR) Stock Price” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.com-unik.info/2018/02/10/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-acorda-therapeutics-acor-stock-price.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.